Spinal COrd NeuromodulaTor by SpIneX and ScoNE to Treat NeurogeniC BladdEr - SCONE "CONTINENCE" Clinical Study

NCT05301335 | Completed DMC FDA Device

• 1 other identifier: SPNX-001
• Study Type: interventional
• Target: 126
• Locations: 3 countries
• Sites: 12

Brief Summary

The purpose of this study is to evaluate the effectiveness and safety of SCONE neuromodulation therapy after 12 weeks of therapy in comparison to inactive sham control in improving symptoms of Neurogenic Lower Urinary Tract Dysfunction

Conditions

Neurogenic Bladder; Spinal Cord Injuries (Complete and Incomplete); Stroke; Multiple Sclerosis

Outcome Measures

Primary Outcomes (1)

• Neurogenic Bladder Symptom Score (NBSS)

  Lower score represents improvements

  12 weeks

Secondary Outcomes (2)

• Urge Urinary Incontinence Episodes

  12 weeks

• Patient Global Improvement Index (PGI-I)

  12 weeks

Study Arms (2)

Therapeutic Arm

EXPERIMENTAL

Device: SCONE

Sham Arm

SHAM COMPARATOR

Device: SCONE

Interventions

SCONE DEVICE

The Spinal COrd NEuromodulation(SCONE) device delivers a sufficient electrical signal non-invasively to activate the neural structures of the spinal cord without cutaneous discomfort. Rather than relying on stimulation of peripheral nerves, SCONE modulates the CNS directly via the spinal cord. Importantly, SCONE is a technique that enables electrical stimulation of the spinal cord without the need for insertion or implantation of stimulating electrodes

Sham Arm; Therapeutic Arm

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subject is ≥ 18 and ≤ 70 years old (male subjects) or ≥ 18 and ≤ 75 years (female subjects) at the time of enrollment/consent.
• Subject has a diagnosis of NLUTD due to:
• Chronic, spinal cord injury at C3 to T8 classified as ASIA A-B on the AIS scale OR
• Chronic, spinal cord injury at C3 to L1 classified as ASIA C-D on the AIS scale OR
• Multiple sclerosis; OR
• Stroke
• Subject has symptoms of urinary urgency (\> 50% high urge voids) or increased frequency of micturition/self-catheterization (more than once every 2 hours) or incontinence between voids or catheterizations (\> 5/day).
• Subject has sterile urine or asymptomatic bacteriuria.
• Subject's score is \> 28 on NBSS survey.
• Subject is at least one year post initial diagnosis of NLUTD at the time of enrollment (consent).
• Subject's medical condition is stable.
• Subject has adequate social support network to be able to participate in training and assessment sessions for the duration of the study, at the discretion of the Investigator.
• Subject has been informed of the nature of the study, can understand the requirements of the study, agrees to participate, and has signed the IRB/REB/EC-approved informed consent.

You may not qualify if:

• Subject relies on an indwelling catheter (urethral or suprapubic) for bladder drainage.
• Subject has a history of bladder augmentation or continent or incontinent urinary stoma or prior bladder surgery.
• Subject has congestive heart failure, pulmonary disease necessitating supplemental oxygen use, chronic kidney disease (Stage III or higher), chronic liver disease (Child Pugh class B or C) or poorly controlled diabetes (if diabetic, HbA1c \> 8.0 within the preceding 6 months).
• Subject has a concurrent neurological disease affecting the central nervous system, other than spinal cord injury or multiple sclerosis or stroke.
• Subject has an implanted central or peripheral neuromodulator.
• Subject has symptomatic, clinically significant autonomic dysreflexia attacks (characterized by headache and systolic blood pressure greater than 180 mmHg) more than once a week.
• Subject is dependent on an electromagnetic medical implant (e.g., cardiac pacemaker or implanted drug pump), ventilation support, or other external device.
• Subject has received intravesical botulinum toxin injection within 12 months preceding enrollment.
• Subject's BMI is \> 35.
• Subject has history of morphologic bladder outlet obstruction (e.g., due to benign prostatic hyperplasia, urethral stricture and /or bladder neck contracture).
• Subject has history of frequent symptomatic urinary tract infections, defined as receiving five or more courses of urinary tract infection directed antibiotics within 12 months prior to enrollment.
• For non catheterizing subjects, post void residual is \> 100 mL measured by bladder ultrasound, bladder scanner, or one time catheterization at the time of enrollment
• For female subjects, history and/or screening responses consistent with pelvic organ prolapse.
• For non catheterizing male subjects older than 55 years of age, screening responses consistent with benign prostatic hyperplasia.
• Subjects with significant stress incontinence (\> 3 stress incontinence episodes per day), defined as incontinence episodes during physical activity such as cough, sneeze, transfers, and other forms of physical activity.

Sponsors & Collaborators

• SpineX Inc.: lead
• Rancho Los Amigos National Rehabilitation Center, Downey, California, United States: collaborator
• Atrium Health, Charlotte, North Carolina, United States: collaborator
• MedStar National Rehabilitation Network, Washington, District of Columbia, United States: collaborator
• University of California, San Diego, California United States: collaborator
• Craig Hospital, Englewood, Colorado, United States: collaborator
• Columbia University, New York City, New York, United States: collaborator
• Institute of Brain and Spine (IBS Hospital), New Delhi, India: collaborator
• International Collaboration On Repair Discoveries (ICORD), Vancouver, British Columbia, Canada: collaborator
• University of Miami, Miami, United States: collaborator
• Mayo Clinic, Rochester, Minnesota, United States: collaborator
• Shepherd Center, Atlanta, Georgia, United States: collaborator
• Spaulding Rehabilitation Hospital, Charlestown, Massachusetts, United States: collaborator

Study Sites (12)

Rancho Research Institute

Downey, California, 90242, United States

Location

UC San Diego Health Systems

San Diego, California, 92093, United States

Location

Craig Hospital

Denver, Colorado, 80113, United States

Location

Medstar National Rehab

Washington D.C., District of Columbia, 20010, United States

Location

University of Miami, Desai Sehti Urology Institute

Miami, Florida, 33136, United States

Location

Shepherd Centre

Atlanta, Georgia, 30309, United States

Location

Spaulding Rehabilitation Hospital Cambridge

Cambridge, Massachusetts, 02138, United States

Location

Mayo Clinic, St. Mary's Campus

Rochester, Minnesota, 55902, United States

Location

Columbia University Irving Medical Centre

New York, New York, 10032, United States

Location

Atrium Health

Charlotte, North Carolina, 28208, United States

Location

ICORD Vancouver

Vancouver, British Colombia, V5Z 1M9, Canada

Location

Insitute of Brain and Spine

New Delhi, New Delhi, India

Location

Related Publications (2)

• Kreydin EI, Abedi A, Morales L, Montero S, Kohli P, Ha N, Chapman D, Abedi A, Ginsberg D, Jann K, Harvey RL, Liu CY. Neural Mechanisms of Poststroke Urinary Incontinence: Results From an fMRI Study. Stroke. 2025 Jun;56(6):1516-1527. doi: 10.1161/STROKEAHA.124.048057. Epub 2025 Apr 10.

  PMID: 40207355 DERIVED

• Ha NT, Abedi A, Ojeda LAM, Montero S, Kohli P, Chapman D, Abedi A, Gaburak P, Ginsberg D, Harvey RL, Liu CY, Jann K, Kreydin E. Using Functional Magnetic Resonance Imaging to Detect Differences in Micturition-Related Brain Activity Between Volitional and Involuntary Detrusor Contractions. Neurourol Urodyn. 2025 Feb;44(2):374-381. doi: 10.1002/nau.25655. Epub 2024 Dec 29.

  PMID: 39737577 DERIVED

MeSH Terms

Conditions

Urinary Bladder, Neurogenic; Spinal Cord Injuries; Stroke; Multiple Sclerosis

Condition Hierarchy (Ancestors)

Neurologic Manifestations; Nervous System Diseases; Urinary Bladder Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Spinal Cord Diseases; Central Nervous System Diseases; Trauma, Nervous System; Wounds and Injuries; Cerebrovascular Disorders; Brain Diseases; Vascular Diseases; Cardiovascular Diseases; Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Demyelinating Diseases; Autoimmune Diseases; Immune System Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: The study is designed as a prospective, multicenter, single blind, two-arm randomized sham-controlled clinical study. Subjects will be randomized into a treatment arm and control (sham) arm in a 2:1 ratio.

Study Record Dates

• First Submitted: March 19, 2022
• First Posted: March 29, 2022
• Study Start: May 25, 2022
• Primary Completion: May 1, 2024
• Study Completion: May 1, 2024
• Last Updated: February 17, 2025

Record last verified: 2024-11

Data Sharing

• IPD Sharing: Will not share

Locations

IN (1); US (10); CA (1)